For advanced filtering and search capabilities, visit the live tracker at os.thediligentobserver.com/tracker.
<aside> 📝
Last Updated: July 13, 2026 | This content is intended for editorial/informational purposes only. Not investment advice or a solicitation to buy or sell securities.
</aside>
<aside> 👉
Have an Angel Network Investment to Announce?
</aside>
It's the most common question we’ve gotten across the 150+ angel deals we’ve featured so far.
Yes. The answer is yes.
So we’ve started testing something new with a few of the angel networks we work with: when we find one that's still open, we push it to their team directly - one deal at a time, deal brief and founder contact included.
Would something like that be interesting to you? Join the waitlist today.
**AGED Diagnostics | Genomic blood test for liver disease**
Participating Group: Park City Angels
AGED Diagnostics is developing noninvasive blood tests for liver disease, including MASH (an advanced form of fatty liver disease) and liver fibrosis. The company says its platform stages fibrosis across the full disease spectrum and could reduce reliance on biopsies and imaging. According to AGED, roughly 90% of patients remain undiagnosed until disease has advanced. Park City Angels recently announced an additional follow-on investment to support continued development of the company's precision diagnostics approach.
Rachel Zayas | Bethesda, MD | April 2026 | Source